Itzel Ivonn López

Dr. Itzel Ivonn López


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMaria Monica Michicotl Meneses
Maria Monica Michicotl Meneses
MTMaria del Rocio Thompson-Bonilla
Maria del Rocio Thompson-Bonilla
CRCesar A Reyes-Lopez
Cesar A Reyes-Lopez
Blanca Estela García-PérezBlanca Estela García-Pérez
Blanca Estela García-Pérez
ILItzel Ivonn López
Itzel Ivonn López
MJMaria Jaramillo-Flores
Maria Jaramillo-Flores
Pomegranate juice (Punica granatum) has been used since ancient times in traditional medicine (Unani Medicine, Ayurveda); its main compounds are anthocyanins and ellagic acid, which have anti-inflammatory, antioxidant, hepatoprotective, and cardiovascular health effects. The objective was to evaluate the effect of pomegranate juice on inflammation, blood pressure, and vascular and physiological markers associated with obesity induced by a high-fat diet in a murine model. The results show that pomegranate juice reduces the concentration of low-density lipoprotein cholesterol (cLDL) 39% and increases the concentration of high-density lipoprotein cholesterol (cHDL) by 27%, leading to a 12%–18% decrease in the risk of cardiovascular diseases (CVD). In addition to reducing blood pressure by 24%, it also had an antiatherogenic effect by decreasing sE-selectin levels by 42%. On the other hand, the juice significantly increased adiponectin levels in adipose tissue, decreased levels of inflammation markers (tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-17A (IL-17A), interleukin-6 (IL-6), interleukin-1β (IL-1β)), and inhibited the monocyte chemoattractant protein-1 (MCP-1). Pomegranate juice requires clinical studies to prove its immunoregulatory and therapeutic effects on cardiovascular and atherogenic risks.

1 November 2020 in Food Research International
Verified
Journal Article
Closed access
ILItzel Ivonn López
Itzel Ivonn López
ADAarón Domínguez-López
Aarón Domínguez-López
ÁMÁngel Miliar-García
Ángel Miliar-García
GEGerardo Norberto Escalona-Cardoso
Gerardo Norberto Escalona-Cardoso
SRSamantha Alejandra Real-Sandoval
Samantha Alejandra Real-Sandoval
MJMaria Jaramillo-Flores
Maria Jaramillo-Flores

9 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Samuel Jaimez AlvaradoSamuel Jaimez Alvarado
Samuel Jaimez Alvarado
ILItzel Ivonn López
Itzel Ivonn López
JSJavier Barragán-De Los Santos
Javier Barragán-De Los Santos
DBDannya Coral Bello-Vega
Dannya Coral Bello-Vega
FRANCISCO-JAVIER ROLDANFRANCISCO-JAVIER ROLDAN
FRANCISCO-JAVIER ROLDAN
MAMaria Magdalena Aguirre-Garcia
Maria Magdalena Aguirre-Garcia
An intriguing aspect of restrictive cardiomyopathies (RCM) is the microbiome role in the natural history of the disease. These cardiomyopathies are often difficult to diagnose and so result in significant morbidity and mortality. The human microbiome, composed of billions of microorganisms, influences various physiological and pathological processes, including cardiovascular health. Studies have shown that gut dysbiosis, an imbalance in the composition of intestinal bacteria, can contribute to systemic inflammation, a key factor in many cardiovascular conditions. An increase in gut permeability, frequently caused by dysbiosis, allows bacterial endotoxins to enter the bloodstream, activating inflammatory pathways that exacerbate cardiac dysfunction. Recent reports highlight the potential role of microbiome in amyloidogenesis, as certain bacteria produce proteins that accelerate the formation of amyloid fibrils. Concurrently, advancements in amyloidosis treatments have sparked renewed hopes, marking a promising era for managing these kinds of diseases. These findings suggest that the gut–heart axis may be a potential factor in the development and progression of cardiovascular disease like RCM, opening new paths for therapeutic intervention. The aim of this review is to provide a detailed overview of the gut–heart axis, focusing on RCM.

5 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ILItzel Ivonn López
Itzel Ivonn López
ÓAÓscar Rodrigo Aguilar-Villegas
Óscar Rodrigo Aguilar-Villegas
YEYoshua Espinoza-Palacios Espinoza-Palacios
Yoshua Espinoza-Palacios Espinoza-Palacios
LRLorena Segura Real
Lorena Segura Real
BPBerenice Peña-Aparicio
Berenice Peña-Aparicio
MAMaria Magdalena Aguirre-Garcia
Maria Magdalena Aguirre-Garcia
Non-communicable diseases (NCDs) are the leading cause of morbidity and mortality worldwide. These conditions have numerous health consequences and significantly impact patients’ lifestyles. Effective long-term treatment is essential since NCDs are irreversible. Therefore, primary healthcare must be both exclusive and of the highest quality, ensuring comprehensive care. The primary goal should be to improve quality of life with a focus on patients, families, and communities, as most of these diseases can be prevented and controlled, although not cured. Several factors have been linked to individual health, including social, cultural, and economic aspects, lifestyle, and certain environmental factors, including work, that can have positive or negative effects. More of these variables may contribute to the onset of NCDs, which are defined by their chronic nature, propensity for prolongation, and generally slow rate of progression. Examples of NCDs include hypertension, type 2 diabetes (T2D), dyslipidemia, and fatty liver disease linked to metabolic dysfunction. The onset of these diseases has been associated with an imbalance in certain microbial niches, such as the gut, which hosts billions of microorganisms performing multiple metabolic functions, such as the production of metabolites like bile acids (BAs), short-chain fatty acids (SCFAs), and trimethylamine N-oxide (TMAO). Therefore, lifestyle changes and personal habits can significantly impact the gut microbiota (GM), potentially preventing chronic diseases associated with metabolism. NCDs are highly prevalent worldwide, prompting increased attention to strategies for modifying the intestinal microbiota (IM). Approaches such as probiotics, prebiotics, synbiotics, and fecal transplantation (FMT) have demonstrated improvements in the quality of life for individuals with these conditions. Additionally, lifestyle changes and the adoption of healthy habits can significantly impact IM and may help prevent chronic diseases related to metabolism. Therefore, the main aim of this review is to analyze and understand the importance of microbiota intervention in the prevention of non-communicable diseases. R3:A1

Verified
Journal Article
Open access
PDF file
ILItzel Ivonn López
Itzel Ivonn López
LCLuis Alejandro Constantino-Jonapa
Luis Alejandro Constantino-Jonapa
Samuel Jaimez AlvaradoSamuel Jaimez Alvarado
Samuel Jaimez Alvarado
FHFernando Hernández-Quiroz
Fernando Hernández-Quiroz
EJEsteban Jorge-Galarza
Esteban Jorge-Galarza
MAMaria Magdalena Aguirre-Garcia
Maria Magdalena Aguirre-Garcia
Cardiac amyloidosis is a rare and progressive condition characterized by the extracellular deposition of amyloid fibrils in multiple organs. Wild-type transthyretin amyloidosis (ATTR-wt) is the most common type affecting subjects above 60 years old. Recent and growing evidence suggests a potential link between GM and cardiac amyloidosis. In this scenario, the aim of the present study is to characterize the gut microbiota (GM), related metabolites and inflammatory biomarkers in ATTR-wt patients. In the ATTR patients we identified Prevotella_9 as the core OTUs (Operational Taxonomic Unit) of this group, alongside Prevotella 7, Prevotellaceae_UCG-003 and Prevotellaceae_NK3B31. In addition, there were increased levels of long fatty acids, including tetradecanoic, hexadecanoic and octadecanoic acids, in the ATTR group. The data obtained suggest that ATTR patients have an altered gut microbiota that could be used as a potential biomarker in metabolic and cardiovascular diseases, as well as a potential predictor of adverse prognosis in ATTR patients. In addition, the intestinal dysbiosis in ATTR patients could be associated with low-grade endotoxemia promoting a pro-inflammatory state due to the translocation of bacterial components, such as LPS (lipopolysaccharide), into blood circulation.